This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GINDOFF, P. R. Articles by FERIN, M. Search for Related Content PubMed PubMed Citation Articles by GINDOFF, P. R. Articles by FERIN, M.

Sustained Effects of Opioid Antagonism During the Normal Human Luteal Phase^*

PAUL R. GINDOFF, RAPHAEL JEWELEWICZ, WYLIE HEMBREE, SHARON WARDLAW and MICHEL FERIN

Departments of Obstetrics and Gynecology and Medicine, Columbia University College of Physicians and Surgeons New York, New York 10032

Address requests for reprints to: Dr. Michel Ferin, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 630 West 168 Street, New York, New York 10032.

The luteal phase of the menstrual cycle is characterized by a progressive decrease in LH pulse frequency. Short term administration of opiate receptor antagonists during the luteal phase increases the release of both LH and PRL. However, the effects of prolonged opioid antagonism throughout the luteal phase are unknown and, hence, the precise role of endogenous opioid peptides in the reproductive cycle remains to be elucidated. In this study, we examine the ability of longer term opioid antagonism during the luteal phase to alter pulsatile LH and PRL release. Naltrexone (NTX), a long-acting oral opioid antagonist, at a dose of 50 mg, was administered daily for 7 days during the luteal phase in five women. Blood samples were obtained at intervals of 10 min starting at 0800 h for 11–12 h on matched days of the luteal phase of both a control and the experimental cycle. LH and PRL pulse frequencies were significantly increased at the end of the 7-day NTX administration period compared to those in the control cycle [LH, 0.22 ± 0.04 (±SE) vs. 0.07 ± 0.03 pulse/h (P < 0.01); PRL, 0.20 ± 0.02 vs. 0.13 ± 0.02 pulse/h (P < 0.05)]. The concordance between LH and PRL pulses increased from 50% in the control cycle to 70% in the NTX cycle, and there was a significant positive correlation between the amplitudes of the concomitant LH and PRL pulses (r = 0.72; P = 0.01).

In conclusion, prolonged oral opioid antagonism increased pulsatile LH and PRL secretion during the luteal phase in normal women. The results underscore the important role of endogenous opioid peptides in controlling LH pulse frequency during the luteal phase of the cycle.

^* Presented at the 34th Annual Meeting of the Society of Gynecologic Investigation, Atlanta, March 1987. This work was supported in part by ACOG-Mead-Johnson Fellowship Award (1985–1986).

Present address: Department of Obstetrics and Gynecology, George Washington University Medical Center, Washington, D.C. 20037.

Received September 18, 1987.

This article has been cited by other articles:

				C. D. Foradori, R. L. Goodman, V. L. Adams, M. Valent, and M. N. Lehman Progesterone Increases Dynorphin A Concentrations in Cerebrospinal Fluid and Preprodynorphin Messenger Ribonucleic Acid Levels in a Subset of Dynorphin Neurons in the Sheep Endocrinology, April 1, 2005; 146(4): 1835 - 1842. [Abstract] [Full Text] [PDF]

				C. D. Foradori, L. M. Coolen, M. E. Fitzgerald, D. C. Skinner, R. L. Goodman, and M. N. Lehman Colocalization of Progesterone Receptors in Parvicellular Dynorphin Neurons of the Ovine Preoptic Area and Hypothalamus Endocrinology, November 1, 2002; 143(11): 4366 - 4374. [Abstract] [Full Text] [PDF]

				C. R. McCartney, M. B. Gingrich, Y. Hu, W. S. Evans, and J. C. Marshall Hypothalamic Regulation of Cyclic Ovulation: Evidence That the Increase in Gonadotropin-Releasing Hormone Pulse Frequency during the Follicular Phase Reflects the Gradual Loss of the Restraining Effects of Progesterone J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2194 - 2200. [Abstract] [Full Text] [PDF]

				C. L. Pastor, M. L. Griffin-Korf, J. A. Aloi, W. S. Evans, and J. C. Marshall Polycystic Ovary Syndrome: Evidence for Reduced Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Estradiol and Progesterone J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 582 - 590. [Abstract] [Full Text]